Tai'ai (telitacicept) / Vor Biopharma, RemeGen - LARVOL DELTA

B-cell-targeted therapy for systemic lupus erythematosus-associated warm autoimmune haemolytic anaemia: a real-world comparative cohort study. (PubMed, Rheumatology (Oxford)) - "Six- and 12-month ORR did not differ significantly between treatment strategies. The numerically higher complete response rate, more stable 12-month response and earlier glucocorticoid reduction with B-cell-targeted therapy, together with the telitacicept findings, are exploratory and require prospective validation."

Journal • Real-world evidence • Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Sustained clinical stability with telitacicept-containing maintenance therapy following glucocorticoid and IVIG induction for lupus enteritis with autoimmune hemolytic anemia: a case report. (PubMed, Front Immunol) - "Standard management relies on high-dose glucocorticoids (GCs) combined with cyclophosphamide (CYC) or mycophenolate mofetil (MMF); however, prolonged glucocorticoid dependence and disease recurrence remain significant clinical challenges...We describe a 27-year-old female with severe, glucocorticoid-dependent LMV complicated by autoimmune hemolytic anemia (AIHA), who received pulse methylprednisolone (MP) and intravenous immunoglobulin (IVIG) for acute induction, followed by telitacicept 160 mg weekly as part of a combination maintenance regimen. After conventional induction, telitacicept was associated with successful prednisone tapering from 60 mg/day to 10 mg/day over approximately 6 months without disease flare, accompanied by sustained normalization of hemoglobin and complement levels, and radiological improvement. This case represents the second report of telitacicept for LMV and the first to document sustained resolution of AIHA maintained during..."

Journal • Anemia • Autoimmune Hemolytic Anemia • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • Vasculitis

A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease (clinicaltrials.gov) - P2 | N=198 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

New P2 trial

LUB006, A Novel and Potent anti-IFNAR1-TACI Antibody Fusion Protein, Demonstrates Synergistic Efficacy in an Systemic Lupus Erythematosus Model by Dual Pathway Inhibition (ACR Convergence 2026) - "The pharmacokinetics (PK), pharmacodynamics (PD) and GLP toxicology study (14-week repeated-dose) of LUB006 were evaluated in cynomolgus monkeys. LUB006 displayed superior BAFF/APRIL binding affinity and blocking activity to Telitacicept and Povetacicept, and comparable IFNAR1 binding affinity and pSTAT1 inhibition to that of Anifrolumab. LUB006 exhibited superior activity against BAFF/APRIL in both in vitro assays and an in vivo PD model compared to competitors. Additionally, we demonstrated the synergistic benefit of dual-pathway inhibition in suppressing B cell proliferation and in a bm12-inducible lupus model. These preclinical findings suggest that LUB006 may offer enhanced therapeutic efficacy for SLE and other autoimmune diseases."

Clinical • Immunology • Inflammatory Arthritis • Lupus • Sjogren's Syndrome • Systemic Lupus Erythematosus • IFNA1 • IFNAR1

ESSDAI and ESSPRI Subdomain Analysis of Telitacicept in Patients With Primary Sjögren Disease (ACR Convergence 2026) - No abstract available

Clinical • Sjogren's Syndrome

Telitacicept reshapes peripheral B- and T-cell compartments and interferon-related programs in systemic lupus erythematosus: insights from single-cell transcriptomic and B-cell receptor profiling (ACR Convergence 2026) - No abstract available

Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Telitacicept Reduces Disease Activity, Modulates B Cell Homeostasis and Interferon Signatures in Chinese Patients with Systemic Lupus Erythematosus: A Prospective Cohort Study (ACR Convergence 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Refractory high-risk mucous membrane pemphigoid treated with Telitacicept (EADV 2026) - No abstract available

Immunology

Effectiveness and safety of telitacicept in refractory ocular myasthenia gravis: a retrospective, real-world study. (PubMed, Front Immunol) - "The median daily prednisone dose was reduced from 15.0 mg (IQR 10.0-22.5) to 9.0 mg (IQR 5.0-13.8) by week 12 (median decrease: 7.5 mg, 95% CI: 2.5-13.5; p = 0.031, r = 0.79), with 1 patient discontinuing corticosteroids by week 8. No serious adverse events, infections, or treatment discontinuations occurred. Telitacicept was associated with rapid, sustained clinical improvement and a favorable safety profile in refractory OMG, which supports its potential role as an add-on therapeutic option."

Journal • Observational data • Real-world evidence • Retrospective data • CNS Disorders • Immunology • Infectious Disease • Myasthenia Gravis

Evaluation of the Efficacy and Safety of Telitacicept combined with MMF or Low-dose Hormones in Patients with IgAN with Low Proteinuria (0.5-1g/d) (ChiCTR) - P4 | N=50 | Not yet recruiting | Sponsor: Second Affiliated Hospital of Shantou University Medical College; Second Affiliated Hospital of Shantou University Medical College

New P4 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease

Efficacy of standard therapy combined with telitacicept in patients with relapsed IgG4-related disease: a prospective clinical trial (ChiCTR) - P=N/A | N=10 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Air Force Medical University of the Chinese People's Liberation Army; The First Affiliated Hospital of Air Force Medi

New trial • Inflammation

Telitacicept for primary angiitis of the central nervous system: A real-world retrospective study. (PubMed, Ther Adv Neurol Disord) - "Telitacicept treatment was associated with improvements in neurological outcomes and reductions in HR-VWI inflammatory parameters in patients with PACNS. HR-VWI may provide valuable information for assessing disease activity and evaluating longitudinal vascular changes during follow-up."

Journal • Real-world evidence • Retrospective data • Inflammation • Vasculitis

Real-world effectiveness of telitacicept in ebv-seropositive patients with systemic lupus erythematosus. (PubMed, Clin Rheumatol) - "In EBV-infected SLE, telitacicept was associated with earlier disease control and reduced glucocorticoid burden without apparent laboratory tolerability concerns. Prospective studies incorporating longitudinal virological monitoring are needed to confirm these findings. Key Points • EBV infection is common in SLE and may promote B‑cell activation, but treatment outcomes in this subgroup are poorly defined. • This study compared telitacicept versus standard care for effectiveness and laboratory tolerability in EBV‑positive moderate‑to‑severe SLE. • Telitacicept shortened time to LLDAS and reduced cumulative glucocorticoid exposure, despite similar LLDAS attainment rates. • EBV reactivation was associated with earlier disease control; no clinically significant laboratory abnormalities were observed."

Journal • Real-world evidence • Epstein-Barr Virus Infections • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • IFNG

Efficacy and safety of telitacicept combined with standard of care in patients with proliferative lupus nephritis: a real-world retrospective study. (PubMed, Lupus Sci Med) - "This real-world study demonstrates that telitacicept combined with SoC significantly improves renal response rates during the induction phase of proliferative LN while reducing glucocorticoid exposure. Consequently, telitacicept may represent a promising and effective therapeutic option for the management of proliferative LN."

Journal • Real-world evidence • Retrospective data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus

BAFF/APRIL-targeted therapy for systemic lupus erythematosus and lupus nephritis: a systematic review and meta-analysis. (PubMed, Clin Rheumatol) - "Available evidence suggests that several BAFF/APRIL-targeted therapies may improve SRI-4 response in SLE, with belimumab supported by the most mature evidence base. Renal benefit is established primarily by BLISS-LN, while evidence for other agents remains uncertain. Findings should be interpreted cautiously because most outcomes were supported by low or very low certainty evidence. Key Points • BAFF/APRIL-targeted therapies may improve SRI-4 response in SLE, although certainty varies substantially across agents and outcomes. • Belimumab has the most mature evidence base, whereas telitacicept shows a promising efficacy signal that requires broader confirmation; no evidence of increased serious adverse-event risk was observed. • The organ-specific evidence map identifies seven important research gaps and should be interpreted alongside the predominantly Low or Very low certainty of evidence."

Journal • Retrospective data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus

Telitacicept in myasthenia gravis: a systematic review of clinical outcomes, steroid-sparing effects, and safety. (PubMed, Front Neurol) - "Current evidence suggests that telitacicept may provide potential clinical benefits and steroid-sparing effects in selected patients with MG. However, the certainty of evidence remains limited because most available studies were retrospective or uncontrolled, and further well-designed randomized controlled trials are required to establish its efficacy, long-term safety, and optimal clinical positioning."

Clinical data • Journal • Review • CNS Disorders • Immunology • Myasthenia Gravis

Comparison of telitacicept and belimumab in systemic lupus erythematosus: a real-word retrospective study. (PubMed, Clin Rheumatol) - "Both telitacicept and belimumab reduced disease activity in SLE. While telitacicept exhibited a numerical trend toward greater C4 elevation in SLE and a potential signal of greater IgG reduction in LN, these findings require validation in adequately powered prospective trials. Key points • This study compared the efficacy of telitacicept and belimumab treatment in SLE, presenting important reference function for clinical medication."

Journal • Retrospective data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus

Atacicept in IgA nephropathy. (PubMed, Expert Rev Clin Immunol) - "This is a very promising finding, and long-term results with atacicept, and a similarly promising BAFF and APRIL inhibitors, telitacicept and povetacicept in nephropathy are eagerly awaited. Of particular interest is whether long-term suppression of immunoglobulins with these inhibitors has adverse effects. Further trials will be needed to determine the respective roles of these inhibitors with angiotensin converting enzyme inhibitors (ACEi) and/or angiotensin receptor blockers (ARBs) and/or sodium-glucose cotransporter 2 (SGLT 2) inhibitors in IgA nephropathy."

Journal • Review • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease

Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis (Yahoo Finance) - "Topline results from the 24-week primary endpoint remain expected in the first half of 2027...Vor Bio also plans to initiate UPSTREAM oMG, a global Phase 3 registrational trial evaluating telitacicept for the treatment of patients with ocular myasthenia gravis, with the first patient dosing anticipated in the first half of 2027."

Enrollment closed • New P3 trial • P3 data: top line • Immunology • Myasthenia Gravis

Management strategies for post-transplant IgA nephropathy in kidney transplant recipients: a scoping review. (PubMed, BMC Nephrol) - "RAAS-blockade was the most commonly used intervention and was associated with benefit in several studies. Tonsillectomy was associated with improved outcomes but reported only in Japanese cohorts. Other interventions (rituximab, pulsed steroids, emerging therapies) warrant prospective clinical trials. Amid evolving paradigms in native IgAN management, this review highlights heterogeneity in diagnostic criteria, outcome reporting, and interventions for the management of post-transplant IgAN. Robust prospective, multicentre studies are urgently required to define optimal management in this high-risk population."

Journal • Glomerulonephritis • IgA Nephropathy • Renal Disease • Transplantation

Efficacy and safety of telitacicept for rituximab-refractory membranous nephropathy. (PubMed, Int Urol Nephrol) - "Telitacicept demonstrates favorable efficacy and acceptable safety in RTX-refractory MN, representing a promising treatment option for this challenging population."

Journal • Glomerulonephritis • Renal Disease

Telitacicept for IgA Nephropathy. (PubMed, N Engl J Med) - No abstract available

Journal • Glomerulonephritis • IgA Nephropathy • Renal Disease

Telitacicept for IgA Nephropathy. (PubMed, N Engl J Med) - No abstract available

Journal • Glomerulonephritis • IgA Nephropathy • Renal Disease

Telitacicept for IgA Nephropathy. Reply. (PubMed, N Engl J Med) - No abstract available

Journal • Glomerulonephritis • IgA Nephropathy • Renal Disease

Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis (clinicaltrials.gov) - P2 | N=420 | Recruiting | Sponsor: Peking University People's Hospital

New P2 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology